Noble Capital Markets Initiates Coverage On YS Biopharma Co With Outperform Rating, Announces Price Target of $5.25
Noble Capital Markets Initiates Coverage On YS Biopharma Co With Outperform Rating, Announces Price Target of $5.25
諾布爾資本市場以跑贏大盤的評級啓動對YS Biopharma Co的報道,宣佈目標股價爲5.25美元
Noble Capital Markets analyst Gregory Aurand initiates coverage on YS Biopharma Co (NASDAQ:YS) with a Outperform rating and announces Price Target of $5.25.
諾布爾資本市場分析師格雷戈裏·奧蘭德以跑贏大盤的評級開始對YS Biopharma Co(納斯達克股票代碼:YS)進行報道,並宣佈目標股價爲5.25美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。